Companies Continue to Expand Prediction Market Investments Amid Regulatory Uncertainty Yardeni Warns Fed May Need July Rate Hike to Appease Bond Vigilantes Amid Incoming Chair Warshs Dilemma Kazatomprom Q3 Production Surges 17 Signaling Strong Uranium Supply Musical Theatre Stars Success Strategies Offer Lessons for Entertainment Investors Pokmon Card Market Boom Nostalgia Speculation and Celebrity Influence The Energy Report Mining Sector Faces Higher Energy Costs and Supply Chain Pressures USPH Q1 2026 Earnings EPS Misses Estimates by Over 17 Stock Declines Sachem Capital Corp 600 Notes due 2027 SCCE Q4 2025 Earnings Massive EPS Surprise Highlights Resilient Operating Performance QURE Q1 2026 Earnings NarrowerthanExpected Loss Amid Gene Therapy Pipeline Progress CMCT Q3 2024 Earnings Significant EPS Miss Amidst Challenging Market Conditions ATNM Q1 2026 Earnings EPS Beat Highlights Cost Discipline as Pipeline Advances Albertsons Companies Inc ACI Q1 2026 Earnings EPS Surpasses Estimates by 103 Amid Operational Resilience MIRA Pharmaceuticals Inc MIRA Slips 866 to 105 as Technicals Test Key Support NAC Trades Flat as Muni Bond Market Holds Steady Support and Resistance in Focus Terns Pharmaceuticals TERN Steadies Near Support Amid Flat Trading Session Kalaris Therapeutics KLRS Surges 772 as Shares Approach Key Resistance Wrap Technologies WRAP Edges Higher While Consolidating Near Key Resistance FedEx Q1 2026 Earnings Strong EPS Beat Driven by Cost Discipline and Operational Efficiency IRM Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency Stock Slips Amplitech Group Inc AMPGZ Q1 2026 Earnings EPS Miss and Steep Stock Decline Highlight Ongoing Challenges ADTX Q3 2025 Earnings Loss Deepens as Cash Burn Accelerates Stock Plunges FITBI Q1 2026 Earnings Depositary Shares Deliver 35 EPS Surprise Amid Flat Stock Reaction NKTR Q1 2026 Earnings WiderThanExpected Loss on No Revenue Workdays New Sana AI Solutions Could Reshape Enterprise Software Landscape ATNM Q1 2026 Earnings NarrowerthanExpected Loss Highlights Continued Clinical Progress AN2 Therapeutics ANTX Rallies 5 as Bulls Test Critical Resistance at 540